Neurogene Inc. Earnings Per Share Disclosure
| December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Outstanding stock options | 8,514,381 | 8,963,945 | |||||||||
| Restricted stock units | 378,500 | 132,000 | |||||||||
| Shares issuable under 2020 ESPP | 49,251 | 53,446 | |||||||||
| 8,942,132 | 9,149,391 | ||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2022 | Mar 20, 2023 | Showing above |
| 2021 | Mar 1, 2022 | |
| 2020 | Mar 25, 2021 | |
| 2019 | Mar 12, 2020 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.